Skip to main content

Table 2 Pulmonary arterial hypertension-specific treatments used during the study

From: Medium-term health-related quality of life in patients with pulmonary arterial hypertension treated with goal-oriented sequential combination therapy based on exercise capacity

Medication Baseline 3 months 6 months 12 months
(n = 30) (n = 30) (n = 29) (n = 28)
ERA 0 30 (100%) 29 (100%) 28 (100%)
PDE-5I 0 2 (7%) 23 (79%) 23 (82%)
Epoprostenol i.v. 0 0 0 1 (4%)
  1. ERA Endothelin receptor antagonist, PDE-5I Phosphodiesterase-5 inhibitor, i.v. Intravenous administration